The global mycoplasma testing market size is valued at an estimated USD 689 million in 2020 and is projected to reach USD 1,095 million by 2025, at a CAGR of 9.7% during the forecast period. The growth of the global mycoplasma testing industry is driven by factors such as the growing concerns over cell culture contamination, growth in the pharmaceutical and biotechnology industries, and rising pharmaceutical R&D activities and investments.
The mycoplasma testing market is highly fragmented and is dominated by various players offering mycoplasma testing products. The major players in this market are Thermo Fisher Scientific, Inc. (US), Charles River Laboratories International, Inc. (US), Lonza Group Ltd. (Switzerland), Merck KGaA (Germany), Roche Diagnostics (Switzerland), American Type Culture Collection (US), Bionique Testing Laboratories, Inc. (US), InvivoGen (US), PromoCell GmbH (Germany), Biological Industries Israel Beit Haemek Ltd. (Israel), Creative Bioarray (US), Mycoplasma Experience (UK), Norgen Biotek Corp. (Canada), Agilent Technologies (US), Biotools B & M Labs, S.A. (Spain), Eurofins Scientific (Luxembourg), GeneCopoeia, Inc. (US), GenBio (Canada), Minerva Biolabs GmbH (Germany), Meridian Bioscience, Inc. (US), Sartorius AG (Germany), Savyon Diagnostics (Israel), Nelson Laboratories Fairfield, Inc. (US), Clongen Laboratories, LLC (US), and ScienCell Research Laboratories, Inc. (Canada).
To know about the assumptions considered for the study download the pdf brochure
Merck KGaA (Germany) has a strong presence across all regions with its distribution channels. Moreover, the company operates through nearly 200 companies in more than 65 countries globally. The company adopted acquisitions as a key strategy to strengthen its position and expand its product portfolio. For instance, in 2020, the company invested USD 21.09 million in a new life sciences laboratory in Buchs, Switzerland, to accelerate and support research & development, analytical production, and quality control.
Roche Diagnostics (Switzerland) is one of the key players operating in the mycoplasma testing market. The company has a strong product portfolio and a global presence in the diagnostics market. Roche has adopted organic and inorganic growth strategies, such as product launches and partnerships, to strengthen its position in this market. In July 2020, the company launched the Cobas 6800 mycoplasma testing instrument in India. With such developments, Roche is aiming to establish its presence in emerging markets such as India.
Mycoplasma Testing Market by Product & Service (Assays, Kits, Reagents), Technique (NAT, ELISA, Staining), Application (Cell Line, End of Production Testing), End User (Biopharmaceutical, Cell Banks, CROs), Region - Global Forecast to 2025
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE